Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5747)	2/26/2002 1:04:19 PM
From: Jibacoa	Respond to of 52153

Yes, it seems RAVEL has so far the best results, and JNJ should be able to get over its Nov.23 H of 60.97 I thought KOSP is going to have a hard time competing with the big boys in the field. It is probably a good product although it still reportedly has 7% drop-out. The product is just getting into the pharmacies and two months from approval is still too short time to tell. The stock seems to have found support at 10.5 The Biotechs seem to be acting better than the market today.<g> SEPR has found support at 36 and should retest the 47 level. RAGL Bernard

To: Biomaven who wrote (5747)	2/26/2002 1:23:37 PM
From: pvw	Read Replies (1) \| Respond to of 52153

Hello Bio Maven: I am new to this board and to Biotech in general. A friend mentioned the company Bio-Rad (BIOA) and sent me this article. sfgate.com I looked it up - studied it (various charts, reports etc..) and bought 100 shares at 68.48. Even though it is thinly traded - it looks solid. Do you know anything about them - or do you have any insights on the long term prospects for such a company ? I plan to hold this one for a few years at least. Thanks for your time. PVW